INCB18424: Phase I/II data

An open-label, dose-escalation, U.S. Phase I/II trial in 153 patients showed that 52% and 49% of patients who received 15 (n=33) or 25

Read the full 237 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE